Sophie Beale

Malton Community Hospital — United Kingdom

Economics, Econometrics and Finance · Social Sciences

18h-index1.2kcitations74works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(7), Cancer Treatment and Pharmacology(5), Diabetes Treatment and Management(4), Lung Cancer Treatments and Mutations(4), HER2/EGFR in Cancer Research(4)

Publications74 total

EE523 Human Metapneumovirus (hMPV): Systematic Literature Review of Economic and Humanistic Disease Burden in Adults
Value in Health·2025
HTA300 Reappraisal Following the Loss of Medicine Patent in HTA Guidelines
Value in Health·2024Open Access
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
Health Technology Assessment·2024· 1 citedOpen Access
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023Open Access
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023· 9 citedOpen Access
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 1 citedOpen Access
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 2 citedOpen Access
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
Health Technology Assessment·2023· 6 citedOpen Access
A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations
BMC Pulmonary Medicine·2022· 18 citedOpen Access
A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations
Research Square (Research Square)·2022· 2 citedOpen Access
Keeping horses barefoot: a shared accomplishment
University of Liverpool·2021· 1 citedOpen Access
Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation
Health Technology Assessment·2020· 61 citedOpen Access
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2020· 6 citedOpen Access
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2020· 3 citedOpen Access
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Health Technology Assessment·2020· 38 citedOpen Access
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
BMC Cancer·2019· 46 citedOpen Access
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics·2018· 8 citedOpen Access
Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer
Medical Decision Making·2018· 4 cited
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics·2018· 14 citedOpen Access
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics·2017· 4 cited
page 1 of 4Next →

Frequent Co-authors

Angela Boland(30), A Bagust(23), Y Dündar(23), Nigel Fleeman(19), J Greenhalgh(18), James Mahon(15), Joanne McEntee(11), Kerry Dwan(10), Eleanor Kotas(10), Marty Richardson(10), Rachel Houten(9), Rumona Dickson(7), Marty Chaplin(7), Sarah J Nevitt(6), Juliet Hockenhull(5), Rui Duarte(5), Chris Proudlove(5), Angela Stainthorpe(4), Carol Lefebvre(3), Julie Glanville(3)